ISIN | LU2389358818 |
---|---|
Valorennummer | 113841304 |
Bloomberg Global ID | UBHCUQU LX |
Fondsname | UBS (Lux) Equity SICAV - China Health Care (USD) Q-acc |
Fondsanbieter |
UBS Asset Management Switzerland AG, Zurich
Basel, Schweiz Telefon: +41 61 288 75 01 E-Mail: sh-ubs-funds-feedback@ubs.com Web: www.ubs.com/fonds |
Fondsanbieter | UBS Asset Management Switzerland AG, Zurich |
Vertreter in der Schweiz |
UBS Fund Management (Switzerland) AG Basel Telefon: +41 61 288 49 10 |
Distributor(en) |
UBS Global Asset Management Basel Telefon: +41 61 288 20 20 |
Anlagekategorie | Aktienfonds |
EFC-Kategorie | Equity Health Care |
Anteilskategorie | Accumulation |
Domizilland | Luxemburg |
Konditionen bei der Ausgabe | Transaktionsgebühr zugunsten des Fonds (Beitrag zur Deckung der Spesen bei der Anlage neu zufliessender Mittel) |
Konditionen bei der Rücknahme | Rücknahmekommission zugunsten der Fondsleitung und/oder des Vertriebsträgers (kann bei gleichem Fonds je nach Vertriebskanal unterschiedlich sein) |
Investment-Strategie *** | The actively managed sub-fund invests mainly in shares and other equity interests of companies related to the healthcare sector domiciled in the People’s Republic of China (“PRC”) or other companies that have close economic links with the PRC. These investments contain securities listed within the PRC (onshore) or outside of the PRC (offshore). This sub-fund promotes environmental and/or social characteristics and complies with Article 8 of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector (“SFDR”). |
Besonderheiten |
Aktueller Preis * | 68.32 USD | 30.09.2024 |
---|---|---|
Vorheriger Preis * | 64.59 USD | 27.09.2024 |
52 Wochen Hoch * | 73.81 USD | 06.11.2023 |
52 Wochen Tief * | 54.68 USD | 30.07.2024 |
NAV * | 68.32 USD | 30.09.2024 |
Ausgabepreis * | 68.32 USD | 30.09.2024 |
Rücknahmepreis * | 68.32 USD | 30.09.2024 |
Schlusskurs * | ||
Indikativer Minimalpreis | ||
Fondsvermögen *** | 2'847'030 | |
Anteilsklassevermögen *** | 5'789 | |
Trading Information SIX |
YTD-Performance | -1.56% |
29.12.2023 - 30.09.2024
29.12.2023 30.09.2024 |
---|---|---|
YTD-Performance (in CHF) | -1.61% |
29.12.2023 - 30.09.2024
29.12.2023 30.09.2024 |
1 Monat | +18.02% |
30.08.2024 - 30.09.2024
30.08.2024 30.09.2024 |
3 Monate | +20.81% |
02.07.2024 - 30.09.2024
02.07.2024 30.09.2024 |
6 Monate | +14.46% |
02.04.2024 - 30.09.2024
02.04.2024 30.09.2024 |
1 Jahr | -0.52% |
09.10.2023 - 30.09.2024
09.10.2023 30.09.2024 |
2 Jahre | +5.17% |
30.09.2022 - 30.09.2024
30.09.2022 30.09.2024 |
3 Jahre | -31.68% |
02.12.2021 - 30.09.2024
02.12.2021 30.09.2024 |
5 Jahre | - | - |
Kapitalbeteiligungsquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anteil am Gesamtvermögen in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immobilienquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Innovent Biologics Inc | 9.18% | |
---|---|---|
Jiangsu Hengrui Pharmaceuticals Co Ltd Class A | 7.19% | |
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A | 6.84% | |
Tencent Holdings Ltd | 5.51% | |
Yunnan Baiyao Group Co Ltd Class A | 4.85% | |
BeiGene Ltd Ordinary Shares | 3.95% | |
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Class H Shares | 3.18% | |
Akeso Inc Ordinary Shares | 2.65% | |
Legend Biotech Corp ADR | 2.46% | |
BeiGene Ltd Class A | 2.37% | |
Letzte Daten-Aktualisierung | 31.08.2024 |
TER | 1.33% |
---|---|
Datum TER | 31.05.2023 |
Performance Fee *** | 0.00% |
PTR | |
Max. Management Fee *** | 1.03% |
Ongoing Charges *** | 1.30% |
SRRI ***
|
|
Datum SRRI *** | 31.08.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |